Chad vs Mexico: Tuberculosis patients living with HIV receiving antiretroviral therapy
Chad
1,543 patients
in 2021
Mexico
1,485 patients
in 2021
Chad rank
30th
Mexico rank
32nd
Tuberculosis patients living with HIV receiving antiretroviral therapy over time
- Chad
- Mexico
How they compare
Chad currently reports 1,543 patients against 1,485 patients in Mexico, a difference of 58 patients.
The two have swapped places 5 times across 14 shared years of data; in 2003 it was Mexico ahead.
Chad ranks 30th and Mexico ranks 32nd of 183 countries.
Across the 3 decades both report, Chad averaged higher in 1 and Mexico in 2.
Head to head by decade
| Decade | Chad | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 99.67 patients | 258 patients | 158.33 patients | Mexico |
| 2010s | 848.22 patients | 1,085 patients | 237.11 patients | Mexico |
| 2020s | 1,437 patients | 1,321 patients | 116 patients | Chad |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis patients living with hiv receiving antiretroviral therapy, Chad or Mexico?
- Chad, at 1,543 patients against 1,485 patients in Mexico as of 2021.
- What is the difference in tuberculosis patients living with hiv receiving antiretroviral therapy between Chad and Mexico?
- 58 patients, with Chad ahead.
- How many years of comparable data are there for Chad and Mexico?
- 14 years are reported by both, from 2003 to 2021.
- How do Chad and Mexico rank globally for tuberculosis patients living with hiv receiving antiretroviral therapy?
- Chad ranks 30th and Mexico ranks 32nd of 183 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026); Population based on various sources (2024) – with minor processing by Our World in Data, published as Tuberculosis patients living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of tuberculosis patients who are living with HIV and receiving antiretroviral therapy.